source
- STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived earlyIn data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.STAT · 17d ago↗ source
- STAT+: Treasury proposes major restrictions to U.S. investment in Chinese biotech sectorA new Treasury Department proposal would restrict U.S. investments in Chinese biotechs, but still allows licensing deals.STAT · 18d ago↗ source
- Moderna and Merck's mRNA melanoma vaccine cuts recurrence risk by 42% in trialA large Phase 2 trial led by Moderna and Merck showed that their personalized mRNA vaccine, intismeran autogene, lowered the chance of melanoma returning by 42% compared with standard therapy. The…